Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Invictus MD Strategies Corp IVITF

Healthcare Drug Manufacturers - Specialty & Generic Cannabis
Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.


GREY:IVITF - Post by User

Invictus MD Strategies Corp
Bullboard Posts
User Avatar Image
(12)
•••
Post by bluemoons20on Jun 22, 2018 3:04pm
232 Views
Post# 28215208

performance

performance
its nice that various folks think GENE is a good value  because of its price relative to others in the space.  However, what is  the reason.  Canopy  rose about 25%  in the last week or so.  And GENE ?  -  still holding steady at being a great value buy???

In my opinion  this does not really make too much sense.  Can someone hepl me understand  what this is all about??  Have been a sharholder for over 2 years  and seems like always the bridesmaid  and never the bride!!
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities